SVB Leerink Weighs in on Pfizer Inc.’s Q3 2022 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFEGet Rating) – Investment analysts at SVB Leerink increased their Q3 2022 EPS estimates for shares of Pfizer in a research report issued on Wednesday, June 22nd. SVB Leerink analyst D. Risinger now anticipates that the biopharmaceutical company will earn $1.91 per share for the quarter, up from their prior estimate of $1.86. SVB Leerink currently has a “Market Perform” rating and a $55.00 price target on the stock. The consensus estimate for Pfizer’s current full-year earnings is $6.61 per share. SVB Leerink also issued estimates for Pfizer’s FY2022 earnings at $6.69 EPS, Q1 2023 earnings at $1.47 EPS, Q2 2023 earnings at $1.41 EPS, Q3 2023 earnings at $1.56 EPS, FY2023 earnings at $5.90 EPS, FY2024 earnings at $4.99 EPS and FY2025 earnings at $4.70 EPS.

Other analysts have also issued research reports about the stock. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a report on Tuesday, May 3rd. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. Barclays set a $52.00 target price on shares of Pfizer in a report on Tuesday, May 17th. Wells Fargo & Company decreased their target price on shares of Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. Finally, The Goldman Sachs Group set a $51.00 target price on shares of Pfizer in a report on Wednesday, May 25th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.26.

Shares of PFE stock opened at $49.07 on Thursday. The firm’s 50 day moving average is $50.57 and its 200 day moving average is $52.22. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $275.33 billion, a P/E ratio of 11.25, a PEG ratio of 0.58 and a beta of 0.76. Pfizer has a 12 month low of $38.82 and a 12 month high of $61.71.

Pfizer (NYSE:PFEGet Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). The business had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business’s quarterly revenue was up 76.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.93 earnings per share.

The company also recently declared a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were given a dividend of $0.40 per share. The ex-dividend date was Thursday, May 12th. This represents a $1.60 annualized dividend and a yield of 3.26%. Pfizer’s payout ratio is currently 36.70%.

In other news, SVP Jennifer B. Damico sold 4,000 shares of the firm’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the sale, the senior vice president now directly owns 15,064 shares of the company’s stock, valued at approximately $760,732. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at $1,907,300. The disclosure for this sale can be found here. Insiders have sold a total of 41,126 shares of company stock valued at $2,075,003 in the last three months. 0.05% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of the stock. New World Advisors LLC bought a new stake in Pfizer during the 3rd quarter valued at about $292,000. EagleClaw Capital Managment LLC increased its stake in Pfizer by 2.1% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 29,959 shares of the biopharmaceutical company’s stock valued at $1,287,000 after purchasing an additional 625 shares in the last quarter. Dark Forest Capital Management LP increased its stake in Pfizer by 8.5% during the 3rd quarter. Dark Forest Capital Management LP now owns 3,186 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 250 shares in the last quarter. MFA Wealth Advisors LLC bought a new stake in Pfizer during the 3rd quarter valued at about $38,000. Finally, Voloridge Investment Management LLC increased its stake in Pfizer by 1,161.8% during the 3rd quarter. Voloridge Investment Management LLC now owns 117,017 shares of the biopharmaceutical company’s stock valued at $5,033,000 after purchasing an additional 107,743 shares in the last quarter. Institutional investors own 66.50% of the company’s stock.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.